2021 Benchmark

Pharma companies press on in fight against drug resistance, yet lag in access to antibiotics.

The 2021 AMR Benchmark evaluates 17 companies with a major stake in the anti-infectives space, including large research-based companies and generic medicine manufacturers. By comparing how they perform across a set of 20 metrics, the Benchmark tracks the progress and gaps in their efforts to keep medicines and vaccines available, despite the rise of drug resistance.

Large R&D-based companies

84%
GSK
Projects in the pipeline: 31
Products on the market: 51
Score breakdown
Research & Development: 93%
Responsible Manufacturing: 87%
Appropriate Access: 80%
Stewardship: 75%
81%
Pfizer
Projects in the pipeline: 13
Products on the market: 116
Score breakdown
Research & Development: 77%
Responsible Manufacturing: 80%
Appropriate Access: 80%
Stewardship: 90%
68%
Johnson & Johnson
Projects in the pipeline: 14
Products on the market: 8
Score breakdown
Research & Development: 50%
Responsible Manufacturing: 80%
Appropriate Access: 72%
Stewardship: 80%
63%
Novartis
Projects in the pipeline: N/A
Products on the market: 109
Score breakdown
Research & Development: 7%
Responsible Manufacturing: 87%
Appropriate Access: 80%
Stewardship: 75%
60%
Sanofi
Projects in the pipeline: 6
Products on the market: 47
Score breakdown
Research & Development: 33%
Responsible Manufacturing: 73%
Appropriate Access: 84%
Stewardship: 60%
58%
Shionogi
Projects in the pipeline: 11
Products on the market: 8
Score breakdown
Research & Development: 70%
Responsible Manufacturing: 93%
Appropriate Access: 4%
Stewardship: 80%
57%
Otsuka
Projects in the pipeline: 4
Products on the market: 1
Score breakdown
Research & Development: 56%
Responsible Manufacturing: 43%
Appropriate Access: 60%
Stewardship: 65%
46%
MSD
Projects in the pipeline: 13
Products on the market: 19
Score breakdown
Research & Development: 47%
Responsible Manufacturing: 73%
Appropriate Access: 29%
Stewardship: 55%

Generic medicine manufacturers

71%
Aurobindo
Projects in the pipeline: N/A
Products on the market: 39
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 67%
Appropriate Access: 60%
Stewardship: 87%
69%
Abbott
Projects in the pipeline: N/A
Products on the market: 85
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 73%
Appropriate Access: 53%
Stewardship: 80%
67%
Viatris
Projects in the pipeline: N/A
Products on the market: 87
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 73%
Appropriate Access: 72%
Stewardship: 53%
63%
Fresenius Kabi
Projects in the pipeline: N/A
Products on the market: 51
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 60%
Appropriate Access: 53%
Stewardship: 80%
60%
Cipla
Projects in the pipeline: N/A
Products on the market: 59
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 67%
Appropriate Access: 40%
Stewardship: 87%
60%
Teva
Projects in the pipeline: N/A
Products on the market: 137
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 60%
Appropriate Access: 47%
Stewardship: 80%
47%
Sun Pharma
Projects in the pipeline: N/A
Products on the market: 52
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 33%
Appropriate Access: 47%
Stewardship: 60%
20%
Alkem
Projects in the pipeline: N/A
Products on the market: 52
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 33%
Appropriate Access: 20%
Stewardship: 0%
15%
Hainan Hailing
Projects in the pipeline: N/A
Products on the market: 43
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 20%
Appropriate Access: 20%
Stewardship: 0%
Room to improve Performance so far

Insights

  • GSK maintains lead in antibacterial and antifungal R&D to target priority pathogens

    GSK's pipeline is the largest evaluated, with 31 projects in the pipeline. It addresses more pathogens designated as ‘critical’ and/or ‘urgent’ threats, and has most vaccines projects underway.

    > To the best practice

  • R&D pipeline grows, but remains small overall

    Since the previous analysis, 22 projects have left the pipeline, but there have been 38 additions. As a result, the pipeline has modestly increased in size, by 15 projects, from 77 to 92.


    > To the analysis

  • Sustained R&D for AMR from most companies

    Only one of the eight companies evaluated is not currently active in R&D targeting priority pathogens. The remaining seven have sustained their involvement, and several have expanded their pipelines. Pfizer and GSK stand out for adding five and four projects, respectively. 

    > To the analysis

  • Which pathogens are receiving most attention in R&D

    The World Health Organization and US Centers for Disease Control have identified the most dangerous pathogens due to resistance. The eight large research-based companies evaluated are developing 92 medicine and vaccine projects that target them. 

    > To the analysis


Get in touch

Back to top |